According to the manufacturer of Bapten, a drug used for the treatment of tendinitis of the superficial digital flexor tendon in the horse, the drug is again on the market. There was a “stop-sale” on Bapten in Oct. 1998 due to “a small number of reports of apparent excessive swelling post treatment,” according to Boehringer Ingelheim.

“After an extensive review, it has been concluded that Bapten remains a safe and highly efficacious product as a tool in the recovery of bowed tendons,” according to literature from Boehringer Ingelheim.